{"id":"brimonidine-purite-0-15","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Ocular hyperemia"},{"rate":"10-15","effect":"Ocular allergic reactions"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL2062257","moleculeType":"Small molecule","molecularWeight":"442.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces the production of aqueous humor while simultaneously enhancing its drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The purite formulation is a preserved formulation designed for topical ophthalmic use.","oneSentence":"Brimonidine is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:37.283Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04007276","phase":"PHASE4","title":"The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Tulane University","startDate":"2026-11-10","conditions":"Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":60},{"nctId":"NCT05480098","phase":"PHASE4","title":"Brimonidine for Intraoperative Hemostasis","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2022-05-26","conditions":"Dermatochalasis of Eyelid, Ptosis, Eyelid, Ectropion","enrollment":""},{"nctId":"NCT04741919","phase":"NA","title":"Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS)","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-11-25","conditions":"Primary Angle Glaucoma Closure Suspect","enrollment":200},{"nctId":"NCT04683159","phase":"NA","title":"Brimonidine Tartrate for Pterygium Surgery","status":"UNKNOWN","sponsor":"Uptown Eye Specialists","startDate":"2021-02","conditions":"Pterygium, Subconjunctival Hemorrhage","enrollment":66},{"nctId":"NCT04647461","phase":"PHASE4","title":"Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial","status":"UNKNOWN","sponsor":"CHA University","startDate":"2019-03-20","conditions":"Glaucoma, Ocular Hypertensive","enrollment":61},{"nctId":"NCT04633954","phase":"NA","title":"Brimonidine for Subconjunctival Hemorrhage From Femtosecond Laser Assisted Cataract Surgery","status":"COMPLETED","sponsor":"Uptown Eye Specialists","startDate":"2019-06-06","conditions":"Subconjunctival Hemorrhage, Cataract Surgery","enrollment":56},{"nctId":"NCT02975557","phase":"PHASE1, PHASE2","title":"Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)","status":"TERMINATED","sponsor":"Sandeep Jain, MD","startDate":"2016-05","conditions":"Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction","enrollment":15},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT03513172","phase":"NA","title":"Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2016-12-15","conditions":"Post-Injection Intraocular Pressure Spikes","enrollment":55},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01105065","phase":"NA","title":"Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2010-03","conditions":"Glaucoma","enrollment":46},{"nctId":"NCT02003534","phase":"PHASE4","title":"A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-07","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":376},{"nctId":"NCT01216943","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":126},{"nctId":"NCT00061529","phase":"PHASE3","title":"A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT00675207","phase":"PHASE4","title":"Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs","status":"COMPLETED","sponsor":"Northwestern Ophthalmic Institute S.C.","startDate":"2006-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":120},{"nctId":"NCT00348400","phase":"PHASE4","title":"Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT00413751","phase":"","title":"Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"","conditions":"Healthy","enrollment":20},{"nctId":"NCT00121147","phase":"NA","title":"Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan","status":"COMPLETED","sponsor":"Hermann Eye Center","startDate":"2003-09","conditions":"Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alphagan P 0.15%"],"phase":"marketed","status":"active","brandName":"Brimonidine purite 0.15%","genericName":"Brimonidine purite 0.15%","companyName":"Northwestern Ophthalmic Institute S.C.","companyId":"northwestern-ophthalmic-institute-s-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brimonidine is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}